A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors

Trial Profile

A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs Everolimus (Primary) ; Ribociclib (Primary)
  • Indications Ependymoma; Glioma; Medulloblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top